Skip to main content

Advertisement

SpringerLink
Log in

Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML N Engl J Med 368:1781–1790

  2. Elliott MA, Tefferi A (2018) Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. Am J Hematol 93:578–587

    Article  Google Scholar 

  3. Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW (2014) Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem 289:5820–5827

    Article  CAS  Google Scholar 

  4. Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW (2013) The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 122:3628–3631

    Article  CAS  Google Scholar 

  5. Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz SS, Stevens BC, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW (2020) Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol 38:1006–1018

    Article  CAS  Google Scholar 

  6. Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A (2014) Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia 28:1363–1365

    Article  CAS  Google Scholar 

  7. Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 90:653–656

    Article  CAS  Google Scholar 

  8. Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, Pollyea DA (2017) Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica 102:207–209

    Article  Google Scholar 

  9. Hinze A, Rinke J, Hochhaus A, Ernst T.(2020) Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. Ann Hematol https://doi.org/10.1007/s00277-020-04152-w

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan

    Yuichi Ikeda, Jun Yamanouchi & Katsuto Takenaka

Authors
  1. Yuichi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Yamanouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsuto Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuichi Ikeda.

Ethics declarations

Conflict of interest

The authors declare that that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikeda, Y., Yamanouchi, J. & Takenaka, K. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation. Ann Hematol 100, 2639–2641 (2021). https://doi.org/10.1007/s00277-020-04185-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04185-1

Search

Navigation